Cover Image: January 2009 Scientific American Magazine See Inside

Do White Blood Cells Make Cancer Deadly?

The ability to spread underlies the killing power of cancer. The process occurs, John Pawelek thinks, when tumor cells fuse with white blood cells—an idea that, if right, could yield new therapies















Share on Tumblr

Pawelek and his colleagues have also found molecular similarities between metastatic cells and macrophages, such as activation of genes linked with movement. In addition, they discovered that these cancer cells apparently produce organelles known as autophagosomes, with which the cells can digest chunks of themselves. Macrophages often produce autophagosomes as a means to snack on themselves while traveling, and cancer cells may do the same.

Pawelek is not the first scientist drawn to the fusion theory. Its earliest proponent was German pathologist Otto Aichel, who proposed it in 1911. It revived again some 50 years later, thanks to experiments showing that implanted tumor cells could spontaneously fuse with cells in lab animals and spread. About the mid-1980s, however, interest faded. David Goldenberg, who conducted some of those studies and is now president of the Garden State Cancer Center in Belleville, N.J., suggests that attention waned because although scientists could see hybrids of foreign and host cells, the tools at the time could not show that such fusions were actually taking place in natural settings. After all, if fusions were happening in cancer patients, both the tumor cells and macrophages would be virtually genetically identical, making it hard to prove that metastatic cells were hybrids.

But now Pawelek believes that technology has caught up and that the evidence lies with cancer patients who received bone marrow transplants. Radiation therapy and chemotherapy kill off bone marrow, which supplies white blood cells to the body. Donated bone marrow would naturally be genetically distinct from the patient, making it possible to see if tumor cells of the host fused with macrophages from the donor.

So far Pawelek and his colleagues have found two possible examples. In one, a boy with type O blood received a bone marrow transplant from his type A brother, and when the bone marrow recipient later developed kidney cancer, the scientists found tumor cells that possessed blood type A. In the other example, a woman who received a bone marrow transplant from her son later developed kidney cancer, and the new tumor contained cells with the male Y chromosome. In both the human examples, however, the investigators could not confirm that the cells contained the host’s genome. It therefore remains possible that these cells were not hybrids but simply came from the donor. On future samples, Pawelek hopes to use forensic DNA analysis techniques that can detect genes from both host and donor in the same cells.

Any searches for hybrids are highly vulnerable to error, cautions stem cell biologist Irving Weissman of Stanford University. “I’ve seen this kind of thing over and over again—when you think you’ve seen a hybrid, it turns out there’s almost always a cell with another cell adhering to it or very close to it.” (Pawelek insists the researchers took care to ensure such mistakes were not made.)

Weissman also cites other studies that show hybrids are actually less cancerous, not more, when tumor cells are fused with normal cells, apparently because the infusion of healthy DNA helps to suppress malignant activity. Pawelek suggests that the cell type used may partially explain this discrepancy—fusions with white blood cells show enhanced malignancy, whereas cell types such as epithelial cells can suppress tumors.

But even if Pawelek shows that the fused cells become metastatic, Vogelstein says, researchers still have to see whether these hybrids account for a significant fraction of metastases or whether other mechanisms trigger most spreading cancers.

If Pawelek is right, investigators will have new ways to combat cancer. For instance, they could aim to develop drugs based on antibodies that attack fused cells that may have unique chemical signatures or to devise therapies that block molecules linked with cell fusion. “Even if he’s wrong,” Vogelstein remarks, “the pursuit of unconventional ideas often leads to novel insights.”



3 Comments

Add Comment
View
  1. 1. bturner 07:23 PM 1/13/09

    Pawelek's hypothesis is very interesting and seems plausible, but unfortunately, the evidence in support of his hypothesis is not strong.

    The forensic DNA analysis approach seems to be the obvious way to go to provide stronger support for this hypothesis. An experiment could be conducted to determine whether macrophage DNA is present or comingled with tumor cell DNA. A fairly simple experiment would be to take bone marrow cells from a donor, label the DNA in the donor cells, then take some tumor cells from the host and label the DNA with another chemical marker. Then put both donor and host cells back into the host and when the cancer spreads to a new area, remove tumor cells from the new area and look for donor DNA mixed with the host's DNA in the tumor cells.

    I would guess that this type of experiment has already been done...maybe no one has come up with results that would back up Pawalek's hypothesis?

    Reply | Report Abuse | Link to this
  2. 2. AVattay 09:16 AM 4/22/09

    Actually it may be worth taking the cell fusion theory one step further beyond metastasis, in an attempt to justify oncogenesis itself based on the following assumptions.
    Genomic fusion between cells generates diversity. This diversity can be selected upon by its environment. In the case of cancer the selection is for uncontrolled cell growth. In theory if one shuffles the genome of a cell most of the cell progeny will be not be viable however the possibility exist that the shuffling event will generate the genetic fusions that we often see in tumor cells.
    Whether or not a macrophage are involved is not the soul issue, indeed a prearranged epigenome of a macrophage should give an advantage for metastasis as compared to other cells when fused to a non metastatic tumor. However the role of cell fusion may not limited to metastasis alone, but rather contribute to the genomic instability that is often seen in cancer.
    Which raises the question, is genomic fusion the driving force in oncogenesis that leads to oncogenes? Maybe the experiment to do would be to take cells that are amendable to fusion such as stem cells, and fuse them together then select for uncontrolled growth as compared to non-fused cells. The hypothesis would be that the diversity generated by the fusion would introduce the necessary mutations to initiate oncogenesis. The counter would be that reverse fusion (mitosis) directs the rearrangement. In any event pursuing the cause of metastasis/oncogenesis whether it is fusion or reverse fusion contributes to our knowledge regardless of the outcome.

    Reply | Report Abuse | Link to this
  3. 3. AVattay in reply to bturner 09:26 AM 4/22/09

    One aspect that should be incorporated into any experiments with cell fusion is using a fusible cell lines such as stem cells.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Do White Blood Cells Make Cancer Deadly?: Scientific American Magazine

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X